Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Sanofi Pasteur SA - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Sanofi Pasteur SA - Product Pipeline Review - 2014', provides an overview of the Sanofi Pasteur SA's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Sanofi Pasteur SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Sanofi Pasteur SA including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Sanofi Pasteur SA's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Sanofi Pasteur SA's pipeline products Reasons to buy - Evaluate Sanofi Pasteur SA's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Sanofi Pasteur SA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Sanofi Pasteur SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Sanofi Pasteur SA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Sanofi Pasteur SA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Sanofi Pasteur SA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Sanofi Pasteur SA Snapshot 6 Sanofi Pasteur SA Overview 6 Key Information 6 Key Facts 6 Sanofi Pasteur SA - Research and Development Overview 7 Key Therapeutic Areas 7 Sanofi Pasteur SA - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Combination Treatment Modalities 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Sanofi Pasteur SA - Pipeline Products Glance 15 Sanofi Pasteur SA - Late Stage Pipeline Products 15 Pre-Registration Products/Combination Treatment Modalities 15 Phase III Products/Combination Treatment Modalities 16 Sanofi Pasteur SA - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Sanofi Pasteur SA - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 Sanofi Pasteur SA - Drug Profiles 21 (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 clostridium difficile vaccine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 dengue [serotyoes 1, 2, 3,4] (tetravalent) vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Rabies VRVg 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Vaxigrip Quadrivalent 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 influenza vaccine (A/H7N9) 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 meningococcal polysaccharide + diphtheria vaccine [serogroups A, C, Y and W-135] 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 tuberculosis vaccine 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 EN41-FPA2 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 EN41-UGR7C 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ETEC Adhesin-Based Vaccine 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 HSV-529 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 pneumococcal vaccine (trivalent) 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 streptococcus pneumonia vaccine 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 vCP-2292 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Prophylactic Vaccine 2 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 vCP-2264 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 vCP-2291 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 universal influenza vaccine 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Sanofi Pasteur SA - Pipeline Analysis 46 Sanofi Pasteur SA - Pipeline Products by Target 46 Sanofi Pasteur SA - Pipeline Products by Route of Administration 48 Sanofi Pasteur SA - Pipeline Products by Molecule Type 49 Sanofi Pasteur SA - Recent Pipeline Updates 50 Sanofi Pasteur SA - Dormant Projects 54 Sanofi Pasteur SA - Discontinued Pipeline Products 55 Discontinued Pipeline Product Profiles 55 Meningitis B Vaccine 55 Sanofi Pasteur SA - Locations And Subsidiaries 56 Head Office 56 Other Locations & Subsidiaries 56 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 60 Disclaimer 60
List of Tables Sanofi Pasteur SA, Key Information 6 Sanofi Pasteur SA, Key Facts 6 Sanofi Pasteur SA - Pipeline by Indication, 2014 8 Sanofi Pasteur SA - Pipeline by Stage of Development, 2014 10 Sanofi Pasteur SA - Monotherapy Products in Pipeline, 2014 11 Sanofi Pasteur SA - Combination Treatment Modalities in Pipeline, 2014 12 Sanofi Pasteur SA - Partnered Products in Pipeline, 2014 13 Sanofi Pasteur SA - Partnered Products/ Combination Treatment Modalities, 2014 14 Sanofi Pasteur SA - Pre-Registration, 2014 15 Sanofi Pasteur SA - Phase III, 2014 16 Sanofi Pasteur SA - Phase II, 2014 17 Sanofi Pasteur SA - Phase I, 2014 18 Sanofi Pasteur SA - Preclinical, 2014 19 Sanofi Pasteur SA - Discovery, 2014 20 Sanofi Pasteur SA - Pipeline by Target, 2014 47 Sanofi Pasteur SA - Pipeline by Route of Administration, 2014 48 Sanofi Pasteur SA - Pipeline by Molecule Type, 2014 49 Sanofi Pasteur SA - Recent Pipeline Updates, 2014 50 Sanofi Pasteur SA - Dormant Developmental Projects,2014 54 Sanofi Pasteur SA - Discontinued Pipeline Products, 2014 55 Sanofi Pasteur SA, Other Locations 56 Sanofi Pasteur SA, Subsidiaries 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
